ABBV: what today's price assumes, in the company's own numbers
At $292.82, the model at each driver's own trend prices ABBV at $138.36. The read below shows which reported driver, if any, closes that gap alone.
For today's price to be right, Revenue has to grow about +51% next year, easing toward the long run after that, with every other line on its own trend. That is above its trend (+10%) and well above the last print (+10%, September 2026). No other line can reach the price on its own.
A local 1.8-point lower/higher bracket runs $128 to $149, still below today's $293; the solved level above is the full price-needs point.
| Moves price | Line | Last print | Trend | Price needs | You |
|---|---|---|---|---|---|
| Revenueyear one · 78 prints | +10%Sep 2026 | +10% | +51% | — | |
| Adjusted gross margin ratio (non-GAAP)level | — | — | unobserved | — | |
| Adjusted R&D + SG&A expense as percent of net revenues (non-GAAP)level | — | — | unobserved | — |
Only Revenue can reach today's price on its own; the other 2 lines are held at trend. Growth bars are first-year rates on fading paths; ratio bars are levels held across the horizon.
the bar is the first-year rate on a path fading to the model's long run with the trend's half-life; the trend path is the kernel's own; the street, where shown, is a forecast
62 trading days on record since 2026-09-12. Since 2026-11-13 the bar moved from +50% to +52%, more than half the prints' own spread. The model was refreshed on 2026-09-22; earlier bars may not compare one-for-one after the driver set changed.
each point is what the price needed on that day, sealed in the read ledger; the dots are the prints that landed; the ledger is written once a trading day from the daily refresh and never edited
Every cell is the model's price with Revenue at that level, the rest at trend. One row, because no second line has a measured sensitivity. The blue cells are where today's price ($293) sits; the other filled cells are model-price positions, not good/bad calls.
Markers outside this local grid: Revenue (across): trend +10% below, last print +10% below.
● the last print · ○ the trend · ◆ you. each cell is the model price with Revenue at that level and every other driver at trend; axes include the price-needs point, trend and last print when available; a growth level is the first-year rate fading like trend, a ratio holds; cells within ±2% of today's price are the line
At the bar, revenue is 2.7× today's in 5 years; at trend, 1.3×. The level is from the income statement.
No stated figure from a counterparty is on file for this name yet.
revenue in FY2025-12-31 compounded along the bar's path and along the trend's path for 5 years; the figures beside it are what named counterparties stated, with sources; Dawo does not divide the two
Each yardstick against the bar on Revenue (+51% next year). Six words, no magnitudes.
Today's price sits 112% above the model at trend. Any one of these levers closes that gap alone; which of them the market is using is not observable from the price.
| Lever | Needs | Reference | Sits | In words |
|---|---|---|---|---|
| Revenue | +51% | +10% | below | Revenue at +51% next year against its trend of +10% |
| The discount rate | 4.3% | 8.0% | below | a 4.3% discount rate against the model's 8.0% (risk-free 5.0%, equity premium 4.0%, beta 0.92) |
| The terminal multiple | — | 15.0× | not observable | out of range: even 30 prices the model at 227.43 against today's 292.82; the model's multiple is 15.0x for Healthcare |
each lever solved alone with every other input at the model's own value; positional words, no verdict
▸ Driver by driver · the numbers
For each driver: the last figure the company printed, with its period; the driver's own trend; the rate today's price needs it to run at, with the others at trend; and where the evidence in filings and calls leans.
| Driver | Last printed | Trend | Price needs | Evidence |
|---|---|---|---|---|
| Revenue | +10.3% 2026-09-30 | +10.3% | +51.0% | no claims yet |
| Adjusted gross margin ratio (non-GAAP) | — | — | can't reach it alone | no claims yet |
| Adjusted R&D + SG&A expense as percent of net revenues (non-GAAP) | — | — | can't reach it alone | no claims yet |
What the filings and calls say
What would change the picture
- Next reported Revenue print clears the read's bar — last print 2026-09-30: 0.10319473
The latest filing
2026-09-03 · AbbVie completes acquisition of Apogee Therapeutics for $10.9 billion in cash, $135.11 per share · open the filing · 6 claims read
2026-08-18 · 8.01,9.01 · open the filing · 1 claims read
How this read is made
The drivers are the lines ABBV itself reports, in a general segments structure, reviewed by integrity_gate. Every figure is a dated print from a filing or a release; no model writes a number. “Price needs” is the first-year rate on a path that fades to the model's long-run rate, solved so the model price equals today's, with the other drivers at their own trend. The evidence is the filings' and calls' own sentences, sorted for direction only. The method is on the methodology page; every read is sealed on the day, then checked against the next print and the market window on the ledger.
Research, not advice. Every figure is a dated print from a filing or release you can open; nothing here is a verdict to adopt, and the view on any name is yours to write.